New Haven, Connecticut
Summary
This clinical-stage biotechnology company focuses on developing targeted protein degradation therapeutics using a proprietary platform. Their mission is to improve the lives of patients with serious diseases, particularly in oncology and neuroscience, by creating transformative medicines that challenge traditional drug discovery limits. The company emphasizes innovation, collaboration with leading drug companies, and a commitment to patient advocacy.